摘要
目的比较司帕沙星(SPLX)与洛美沙星(LMLX)的临床抗感染作用。方法将24例呼吸道和泌尿道等感染患者随机分为SPLX和LMLX两组。SPLX组口服剂量为200～300mg ,每日1次 ;LMLX组口服剂量为200～400mg,每日2次。临床疗效按痊愈、显效、进步和无效四级标准判定。痊愈和显效合计为有效。结果SPLX组的总用药量显著少于LMLX组 ,但痊愈率和有效率略高于LMLX组。受试患者的细菌分离率为91 7 % ,在停药第11天两组的细菌清除率为81 8 %和75 0 %。两组均未观察到药物不良反应。结论SPLX为治疗细菌性感染的安全有效的氟喹诺酮类药物 。
Aim This study aimed at clinical comparative trial of sparfloxacin (SPLX) with lomefloxacin (LMLX). Methods Twenty four patients with bacterial infections in respiratory tract or urinary tract were randomly seperated to two groups of SPLX and LMLX. After administration of 200～300 mg of SPLX once daily or 200～400 mg of LMLX twice daily, the clinical effects were observed and defined as cure, obvious efficiency, effcativeness and no effect. Results Isolation rate of bacteria from patients was 91.7%.Total intake amount of SPLX was significantly less than that of LMLX, but cure rate and effective rate in group SPLX were significantly higher than in group LMLX. There were no adverse drug ractions in both groups. Conclusions SPLX is a safe and effective drug among fluoroquinolones in treatment of bacterial infections. The ratio of effect over dose of sparfloxacin is higher than that of lomefloxacin.
